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Reactive oxygen species and reactive nitrogen species (RONS) are by-products of
aerobic metabolism. RONS trigger a signaling cascade that can be transduced
through oxidation-reduction (redox)-based post-translational modifications (redox PTMs)
of protein thiols. This redox signaling is essential for normal cellular physiology and
coordinately regulates the function of redox-sensitive proteins. It plays a particularly
important role in the brain, which is a major producer of RONS. Aberrant redox
PTMs of protein thiols can impair protein function and are associated with several
diseases. This mini review article aims to evaluate the role of redox PTMs of protein
thiols, in particular S-nitrosation, in brain aging, and in neurodegenerative diseases.
It also discusses the potential of using redox-based therapeutic approaches for
neurodegenerative conditions.
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S-nitrosation
INTRODUCTION
Reactive oxygen species and reactive nitrogen species (RONS) are essential signaling molecules
produced by the aerobic metabolism (Friedman, 2010a; Finkel, 2011; Sbodio et al., 2019). One
essential route to transduce RONS signaling is through oxidation-reduction (redox)-based
post-translational modifications (PTMs) of proteins (Stadtman, 1988; Stadtman and Levine, 2003;
Finkel, 2011; Santos and Lindner, 2017).
The mammalian brain is metabolically very active and is a major producer of RONS
(Colton and Gilbert, 2002; Friedman, 2010a,b). Therefore, RONS-dependent redox signaling
is particularly important in the normal physiology of the brain (Colton and Gilbert, 2002;
Beckhauser et al., 2016). Under pathological conditions, RONS can reach excessive levels,
generating oxidative and nitrosative (O/N) stresses, which can damage DNA, lipid, and proteins
and be detrimental to cell function (Jones, 2006; Ray et al., 2012). O/N stresses are active
contributing factors to the pathophysiological mechanisms underpinning neurodegenerative
conditions including Alzheimer’s disease (AD), Parkinson’s disease (PD) and amyotrophic
lateral sclerosis (ALS; Friedman, 2010a,b; Kim et al., 2015; Liu et al., 2017; Sbodio et al., 2019).
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In aerobic organisms, RONS are constantly produced by
the mitochondrial oxidative phosphorylation (OXPHOS) system
and by several enzymes [e.g., NADPH oxidases (NOXs)
and nitric oxide synthases (NOSs); Ignarro, 1990; Raha and
Robinson, 2000; Forman et al., 2002; Bian and Murad, 2003;
Murphy, 2009; Lambeth and Neish, 2014; Nayernia et al., 2014;
Di Meo et al., 2016; Ma et al., 2017; Moldogazieva et al., 2018;
Barua et al., 2019; Sbodio et al., 2019; Gantner et al., 2020].
Some of the major RONS include hydrogen peroxide (H2O2),
hydroxyl radical (•OH), superoxide anion (O•−2 ), peroxyl radical
(ROO•), singlet oxygen (1O2), nitic oxide or nitrogen monoxide
(•NO), nitrogen dioxide (•NO2), and peroxynitrite (ONOO−;
Commoner et al., 1954; McCord, 2000; Forman et al., 2002;
Pham-Huy et al., 2008; Di Meo et al., 2016; Sbodio et al.,
2019). A tightly regulated machinery of small molecules [e.g.,
cysteine, ascorbate, glutathione (GSH)] and proteins [e.g.,
superoxide dismutases (SODs), catalases (CATs), glutathione
peroxidases (GPXs), peroxiredoxins (PRDXs)] reduce RONS
to control their levels in cells (Forman et al., 2002; Birben
et al., 2012; Moldogazieva et al., 2018; Paul et al., 2018;
Sbodio et al., 2019). Under normal physiological (eustress)
conditions, RONS production and reduction are balanced;
however, any imbalance can generate O/N stresses (Jones,
2006; Moldogazieva et al., 2018; Sies, 2019). Crosstalk between
ROS and RNS, their specific sources and scavengers regulate
the distribution of the various RONS present in cells (RONS
composition), their relative abundance and absolute levels
(Forman et al., 2002; Daiber, 2010; Dikalov, 2011; Schulz et al.,
2014; Daiber et al., 2017). This complex network of RONS
triggers a downstream cascade of events, termed redox signaling
(Forman et al., 2002, 2014; Jones, 2006; Ray et al., 2012;
Moldogazieva et al., 2018).
This mini review article focuses on the signaling triggered by
RONS and transduced through redox PTMs of protein thiols and
highlights key features of this signaling in normal cell physiology.
It also assesses the role played by this redox signaling in brain
aging and neurodegenerative conditions. Lastly, it aims to argue
for greater considerations of the complexities of this essential
signaling when designing new redox-based therapeutic strategies
for neurodegenerative diseases.
REDOX POST-TRANSLATIONAL
MODIFICATIONS (PTMs) OF PROTEIN
THIOLS AND THEIR ROLE AS A REDOX
SWITCH FOR PROTEIN FUNCTION
Proteins are the main targets of RONS in cells as a result
of their high rate constants for oxidation reactions and their
abundance (Stadtman and Levine, 2003; Davies, 2005, 2016;
Wall et al., 2012; Moldogazieva et al., 2018). Redox PTMs can
occur nearly on any amino acid side chains (Stadtman and
Levine, 2003; Dickinson and Chang, 2011; Wall et al., 2012;
Corcoran and Cotter, 2013; Go and Jones, 2013). Nitration
can modify tyrosine residues, and carbonylation can modify
lysine, arginine, proline and threonine residues; however, these
modifications are generally stable or irreversible and associated
with O/N stresses (Dickinson and Chang, 2011; Wall et al.,
2012; Corcoran and Cotter, 2013; Houée-Lévin et al., 2015;
Weng et al., 2017; Gonos et al., 2018). Redox PTMs of thiol-
containing cysteine (Cys) residues are considered to be one
of the main drivers of redox signaling in cells because these
residues can be easily oxidized and their oxidation is mostly
reversible, with rates of oxidation and reduction compatible
with signaling initiation and transduction (Miseta and Csutora,
2000; Davies, 2005, 2016; Bindoli et al., 2008; Schöneich, 2011;
Wall et al., 2012; Wani et al., 2014; Go et al., 2015). The
electronic structure of the thiol group (–SH) of Cys residues
enables multiple oxidation states from −2 to +6 leading to a
range of reversible and irreversible redox PTMs (Reddie and
Carroll, 2008; Wang et al., 2012b; Chung et al., 2013; Cremers
and Jakob, 2013; Wani et al., 2014; Figure 1A). Suggesting a
potential cross-regulation between different PTMs, Cys residues
can be targeted by a number of redox PTMs; for instance,
the active Cys sites of protein disulfide isomerase (PDI) can
be S-nitrosated or S-glutathionylated (Halloran et al., 2013).
Besides, an interconversion between redox PTMs can also occur,
with sulfenic acid (–SOH) representing a potential precursor
for other reversible redox PTMs, such as S-glutathionylation,
or intramolecular disulfide bond formation, possibly through
sequential thiol modifications (Gallogly andMieyal, 2007; Mieyal
et al., 2008; Poole and Nelson, 2008; Sabens Liedhegner et al.,
2012). The precise mechanisms underlying cross-regulation
and interconversion between different redox PTMs of protein
thiols remain unclear and future studies investigating multiple
redox PTMs in parallel and over appropriate time-course will
be required to fully explore these important aspects of redox
PTMs regulation.
Mass spectrometry-based redox proteomic studies that have
mapped the redox-modified Cys residues across the proteome
(redox Cys-proteome) have shown that, for a given condition,
only a very specific subset of Cys residues is redox-modified,
demonstrating that RONSmodify Cys residues in a very selective
manner (Doulias et al., 2010; Marino and Gladyshev, 2010, 2012;
McDonagh et al., 2014; Gould et al., 2015; Raju et al., 2015;
Araki et al., 2016; Sun et al., 2016; Topf et al., 2018; van der
Reest et al., 2018; Mnatsakanyan et al., 2019; Xiao et al., 2020).
This selectivity is modulated by several factors including the
pKa of the –SH moiety of the Cys residue, its accessibility,
the other PTMs present in the target protein, and the charges
of the neighboring amino acids and local electrostatic effects
(Hess et al., 2001; Davies, 2005; Doulias et al., 2010; Marino
and Gladyshev, 2010, 2012; Chung et al., 2013; Roos et al.,
2013; Gould et al., 2015; Sun et al., 2016; Mnatsakanyan et al.,
2019; Xiao et al., 2020). Many potential consensus motifs have
been identified and proposed as a chemical rationale that could
underlie the redox sensitivity of specific Cys residues in a given
protein (Stamler et al., 1997; Doulias et al., 2010; Marino and
Gladyshev, 2010, 2012; Chen et al., 2014, 2015; Gould et al., 2015;
Sun et al., 2016; Topf et al., 2018; Mnatsakanyan et al., 2019; Xiao
et al., 2020). The variety of consensus motifs proposed so far may
partly reflect the wide range of experimental and computational
approaches employed to identify the protein thiols that are
modified by redox PTMs. Indeed, several studies have focused
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on endogenous redox PTMs while others have studied redox
PTMs induced by exogenously applied RONS (e.g., H2O2, S-
Nitroso-l-cysteine, S-Nitrosoglutathione, etc.), and an array of
proteomic approaches with varying degrees of sensitivity and
selectivity has been used across studies. Thus, finding unifying
motifs and rules overarching the specificity of redox PTMs
on a proteome-wide scale remains an outstanding challenge.
It has been proposed that under eustress, for a given RONS
composition, RONS absolute levels, and relative abundance,
only a subset of redox-sensitive Cys residues within a protein
is potentially susceptible to several redox-PTMs. In contrast,
O/N stresses can lead to aberrant redox PTMs including redox
PTMs on even lowly-reactive Cys residues, and/or addition of
excessive, persistent or irreversible redox PTMs (Chung et al.,
2013). This continuum of reactivity of Cys residues in redox-
sensitive proteins may provide a redox-sensing mechanism
for cells to monitor RONS composition and RONS levels in
the cellular environment and to coordinate an appropriate
downstream response.
Redox PTMs on proteins act as a ‘‘redox switch’’ that
dynamically regulates protein function (Go and Jones, 2013; Go
et al., 2015; Fra et al., 2017). Redox PTMs can lead to structural
changes in the target protein through disulfide bond formation,
including intramolecular disulfide bonds, Cys-dependent metal
cofactor interactions, and through alteration of the topography
of the protein (Davies, 2005; Khoo and Norton, 2011; Wani
et al., 2014). The way redox PTMs affect protein conformation
is partly dictated by the position of the modified Cys residue in
the target protein, e.g., on the protein surface or buried, or on the
protein backbone or side-chains (Dean et al., 1997; Davies, 2005).
It remains difficult to predict the precise effect of redox PTMs
on protein structure and function, and thus computational and
experimental approaches need to be combined to fully uncover
the functional consequences of redox PTMs on a given protein
(Raimondi et al., 2014; Wani et al., 2014). Redox PTMs can also
modulate the stability and degradation of target proteins (Pajares
et al., 2015, 2018). It has been suggested that depending on the
degree of oxidation of a protein (esp. whether its redox PTMs
are reversible or irreversible), degradation can occur through
either ATP- and polyubiquitination-dependent or independent
mechanisms (Pajares et al., 2015; Song et al., 2016). Redox PTMs
can induce conformational changes that expose hydrophobic
structures normally buried in the natively folded protein; these
structures become recognition and binding surfaces for the 20S
core subunit of the proteasome, which subsequently degrades
the oxidized target protein (Grune et al., 1997; Jung and Grune,
2008; Jung et al., 2014). The redox state of protein thiols can
also regulate the localization of target proteins (Wani et al.,
2014). Importantly, redox PTMs can ultimately tune the activity
of redox-sensitive enzymes and regulate their enzymatic cycle
and recycling (Klomsiri et al., 2011). For instance, the function
of the redox-sensitive protein, Prdx2, is regulated by a redox
switch (Rhee and Kil, 2017). Depending on the cellular RONS
composition and levels, the various residues of Prdx2 can be
decorated by an array of different redox PTMs (Fang et al.,
2007; Park et al., 2011; Engelman et al., 2013; Peskin et al.,
2013, 2016; Wong et al., 2013; Randall et al., 2014, 2019; Salzano
et al., 2014; Svistunova et al., 2019; Figure 1A). Redox PTMs of
Prdx2 regulate its conformation (Wood et al., 2003; Barranco-
Medina et al., 2009; Hall et al., 2009, 2011), catalytic cycle
(Woo et al., 2005; Hall et al., 2009; Karplus, 2015; Rhee, 2016),
degradation (Song et al., 2016) and secretion (Salzano et al., 2014;
Mullen et al., 2015; Figures 1B–F). Crucially, redox PTMs can
coordinately regulate Prdx2 multiple functions as an antioxidant
enzyme and a chaperone. For example, overoxidation (Prdx2-
SO2/3) or S-nitrosation (Prdx2-SNO) of Prdx2 can inactivate
its antioxidant activity, while Prdx2-SO2/3 stabilizes Prdx2
high-molecular weight chaperone complexes (Wood et al., 2003;
Jang et al., 2004; Fang et al., 2007; Hall et al., 2009, 2011; Rhee and
Woo, 2011; Saccoccia et al., 2012; Rhee and Kil, 2017; Svistunova
et al., 2019).
By acting as a redox switch for protein function, redox
PTMs allow for proteins to carry out different functions in
different subcellular compartments. Indeed, the nature of the
redox PTMs on protein thiols is greatly determined by the
RONS composition and pH of the environment surrounding the
target protein (Pace and Weerapana, 2013; Roos et al., 2013).
Therefore, when a protein shuttles to a different compartment
with a different RONS composition and pH, the redox PTMs
of the protein as well as its activity will change accordingly (Go
and Jones, 2008; Jones and Go, 2010). Together, redox PTMs of
protein thiols constitute a powerful mechanism that allows for
a very dynamic and compartment-specific regulation of protein
functions in cells.
ROLE OF REDOX PTMs OF PROTEIN
THIOLS IN CELL PHYSIOLOGY AND
BRAIN AGING
Advances in redox proteomics have allowed to explore further
the functional role of redox PTMs of protein thiols in cell and
organ physiology. In particular, a recent study has mapped the
oxidized Cys residues landscape in ten different tissues from
wild-type mice using a highly sensitive and specific approach
(a Cys-reactive phosphate tag method) and has shown that
oxidized Cys residues were detected in almost half of all
proteins in all tissues tested suggesting that redox PTM of
protein thiols is a widely used signaling mechanism in normal
cellular physiology (Go et al., 2011; Xiao et al., 2020). Analyses
of the redox Cys-proteome across subcellular compartments
also demonstrated that redox PTM of protein thiols occurs in
all subcellular compartments, from nucleus, cytoplasm, Golgi,
endoplasmic reticulum (ER) to mitochondria (Go et al., 2011;
Chung et al., 2013; Doulias et al., 2013; Xiao et al., 2020).
Redox PTMs have been shown to regulate the activity of
proteins implicated in a range of major cellular functions,
and cell survival/death (Trachootham et al., 2008; Brigelius-
Flohé and Flohé, 2011; Handy and Loscalzo, 2012; Wall
et al., 2012; Mailloux et al., 2014; Niforou et al., 2014;
Go et al., 2015; Jones and Sies, 2015; Pajares et al., 2015;
Nakamura and Lipton, 2017; Figure 2A). In particular, redox
PTMs play an essential role in the regulation of energy
metabolism in cells through S-nitrosation, S-glutathionylation,
or S-sulfenylation of proteins of the mitochondrial respiratory
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FIGURE 1 | A redox switch modulates the multiple functions of Peroxiredoxin 2 (Prdx2). (A) The various residues of Prdx2 can be modified by S-sulfenylation
(–SOH), intermolecular and intramolecular disulfide bonds (–SS–), S-sulfinylation (–SO2H), S-nitrosation (–SNO), S-glutathionylation (–SSG), S-sulfonylation (–SO3H),
nitration (–NO2), and carbonylation (–CO: carbonyl groups). Only a subset of all the post-translational modifications (PTMs) that have been described for Prdx2 is
shown here for clarity. (B) The redox state of the Cys residues of Prdx2 regulates its conformation as a dimer, decamer, or high molecular weight complex: the
reduced and overoxidized dimers strongly tend to form decamers or high molecular weight complex, while oxidized forms are preferentially present as dimers.
(C) Depending on its redox PTMs and conformation, Prdx2 can act as an antioxidant enzyme or as a chaperone. Multiple redox PTMs can coordinately regulate
Prdx2 functions. (D) As part of Prdx2 catalytic cycle, its conserved peroxidatic cysteine (CP) first reduces H2O2 or ROOH (peroxidation step). Then a second free thiol
(CR or resolving cysteine) forms a disulfide bond with its CP residue (resolution step). The catalytic cycle is completed when the disulfide bond is recycled, typically by
a thioredoxin-like molecule (Trx), regenerating the free thiol forms of the CP and the CR residues (recycling step). CP-SOH Prdx2 can react with a second ROOH
molecule before it can react with CR-SH, becoming overoxidized (CP-SO2H); this in turn inactivates Prdx2 peroxidase activity. CP-SO2H can be reduced by
sulfiredoxin (Srx). (E) Oxidation of Prdx2 active site (Cys51) triggers conformational changes that bring to the protein surface of Prdx2 a flexible C-terminus that is
subsequently polyubiquitinated; this leads to degradation of oxidized Prdx2 by the proteasome and autophagy. (F) Redox PTMs of Prdx2 can also regulate its
secretion in the extracellular space. Upon exposure to inflammatory stimuli (e.g., LPS or TNF-α), Prdx2 Cys51 and Cys172 residues are oxidized forming
disulfide-linked homodimers and mixed disulfides with glutathione, which triggers its secretion in exosomes into the extracellular milieu. Prdx2, peroxiredoxin 2; CP,
peroxidatic Cys residue; CR, resolving Cys residue; LPS, lipopolysaccharide; TNF-α, tumor necrosis factor-α; Trx, Thioredoxin; Srx, Sulfiredoxin.
complexes I, II, IV, and V, and ATP synthase (Hurd et al.,
2008; Garcia et al., 2010; Handy and Loscalzo, 2012; Wang
et al., 2013; Mailloux et al., 2014; Nakamura and Lipton, 2017;
van der Reest et al., 2018; Xiao et al., 2020), enzymes of the
tricarboxylic acid cycle (e.g., Alpha-ketoglutarate dehydrogenase,
Isocitrate dehydrogenase, Aconitase; Kil and Park, 2005; McLain
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et al., 2013; Yan et al., 2013; Bulteau et al., 2017; Nakamura
and Lipton, 2017, 2020; Xiao et al., 2020), enzymes of glycolysis
[e.g., Hexokinase, Glyceraldehyde 3-phosphate dehydrogenase
(GAPDH); Riederer et al., 2009; Mailloux et al., 2014; McDonagh
et al., 2014; Araki et al., 2016; van der Reest et al., 2018;
Xiao et al., 2020] and of fatty acid metabolism (e.g., Very long
chain acyl-coenzyme A dehydrogenase; Doulias et al., 2013).
Similarly, for proteostasis, redox PTMs have been reported on
chaperones (e.g., Heat shock protein 70, PDI; Wang C. et al.,
2012; Grunwald et al., 2014), subunits of the proteasome (Aiken
et al., 2011; Jung et al., 2014; Kors et al., 2019), and proteins
involved in autophagy (e.g., Autophagy Related 3, 4 and 7;
Frudd et al., 2018; Pajares et al., 2018; Scherz-Shouval et al.,
2019), which ultimately contribute to the regulation of protein
folding and degradation (Niforou et al., 2014; Pajares et al.,
2015). Redox PTMs can also regulate the activity of several
transcription factors (Brigelius-Flohé and Flohé, 2011). For
instance, oxidation, S-nitrosation or nitration of p53, activating
protein 1, myocyte enhancer factor 2 or nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-kB) modulate the
DNA binding and activity of these important transcription
factors (Abate et al., 1990; Schreck et al., 1991; Rainwater et al.,
1995; Klatt et al., 1999; Kabe et al., 2005; Yakovlev et al., 2007;
Jung et al., 2008; Ljubuncic et al., 2008; Okamoto et al., 2014;
Caviedes et al., 2020). Redox PTMs can also affect the activity of
transcription factors through indirect mechanisms. For example,
redox PTMs on Kelch-like ECH-associated protein 1 (Keap1)
trigger the dissociation of the cytoplasmic complex formed by
Keap1 and nuclear factor erythroid 2-related factor 2 (Nrf2),
which allows Nrf2 to translocate to the nucleus and to bind to
the antioxidant response element of its target genes (Dinkova-
Kostova et al., 2002, 2017; Rachakonda et al., 2008).
More globally, comprehensive functional analyses on the
redox Cys-proteomes of various cell types and tissues have
demonstrated that redox PTMs can regulate whole networks of
proteins that share similar biological activities (Doulias et al.,
2010; Go et al., 2011, 2015; Xiao et al., 2020). Importantly,
this coordinated redox-based regulation of functional protein
networks underpins, at least in part, the unique physiological
and metabolic states that characterize the different cell types and
tissues present in organisms. Indeed, redox PTMs of protein
thiols can tune the activity of ubiquitously expressed proteins
in a tissue-specific manner and can also regulate functional
networks specifically in different tissues to control both tissue-
ubiquitous functions (e.g., tRNA aminoacylation) and tissue-
specific functions (e.g., catabolism of glycogen and glucose;
Doulias et al., 2013; Xiao et al., 2020). Therefore, redox PTMs
of protein thiols play an essential part in normal cell physiology
and coordinately regulate functional networks in a tissue- and
cell type-specific manner.
Aging is characterized by molecular and cellular hallmarks
including, but not limited to, altered mitochondrial function,
impaired energy metabolism, increased O/N stresses, and loss
of proteostasis (López-Otín et al., 2013; Figure 2B). Many
aspects of the fundamental molecular mechanisms of brain
aging remain unknown (Mattson and Arumugam, 2018). The
‘‘free radical theory of aging’’ postulates that aging is driven
by an accumulation of harmful and irreversible RONS-induced
damage to DNA, lipids, and proteins (Harman, 1956, 2006). In
accordance with this theory, an increase in modified proteins
(e.g., S-nitrosated Cys residues, and nitrated and carbonylated
amino acids) has been observed in the brain of aging rodents
and humans, especially in the hippocampus, substantia nigra and
frontal cortex, brain regions particularly vulnerable to aging-
associated diseases (Smith et al., 1991; Cini and Moretti, 1995;
Farr et al., 2003; Dremina et al., 2005; Siqueira et al., 2005;
Poon et al., 2006b; Gokulrangan et al., 2007; Prokai et al., 2007;
Riederer et al., 2009; Grimm et al., 2011; Venkateshappa et al.,
2012; Ortuño-Sahagún et al., 2014; Perluigi et al., 2014; Cabré
et al., 2017; Gonos et al., 2018). In addition, in line with an
age-dependent increase in O/N stresses, accumulation of redox
PTMs (e.g., S-sulfonylation and excessive disulfide bonds) on
key antioxidant proteins such as PRDXs and SODs has been
described and shown to impair the enzymatic activity of these
proteins (Kurokawa et al., 2001; Navarro and Boveris, 2004; Poon
et al., 2006a,b; Musicco et al., 2009; Pérez et al., 2010; Gottfredsen
et al., 2013; McDonagh et al., 2014; Perluigi et al., 2014).
Irreversible redox PTMs can participate in the aging
process by triggering unfolding and aggregation of proteins
through hydrophobic and electrostatic interactions between
target proteins (Höhn et al., 2017). With time, these aggregates
can be covalently stabilized, rendering protein aggregates
insoluble and non-degradable (Pacifici et al., 1993; Giulivi et al.,
1994; Johnston et al., 1998; Calderwood et al., 2009; Koga
et al., 2011; Höhn et al., 2017). Existing protein aggregates
can undergo further cross-linking reactions with molecules
such as aldehydes and malondialdehyde, products of lipid
peroxidation, resulting in the formation of highly cross-linked
autofluorescent material referred to as lipofuscin, an important
hallmark of aging (Stadtman and Levine, 2003; Terman and
Brunk, 2004; Jung et al., 2007). O/N stresses also impair the
activity of the proteasome through irreversible redox PTMs such
as carbonylation of its subunits, leading to an age-dependent
reduction of protein degradation and further accumulation of
protein aggregates (Friguet, 2006; Jung et al., 2014; Höhn and
Grune, 2014; Lefaki et al., 2017). These protein aggregates may
in turn interfere with cell homeostasis.
Also, aberrant redox PTMs of proteins on Cys and
other residues may be implicated in the impaired energy
metabolism observed in aging (Yap et al., 2009; Barzilai
et al., 2012; López-Otín et al., 2013; Chistiakov et al., 2014;
Jové et al., 2014; Bouzier-Sore and Bolaños, 2015; Goyal
et al., 2017; Mattson and Arumugam, 2018; Rizza et al.,
2018; Hipkiss, 2019; Ravera et al., 2019). For instance,
3-nitrotyrosine and carbonylation have been detected on energy-
related enzymes, proteins of the mitochondrial respiratory
complex and ATP-synthase in aged rats, in the senescence-
accelerated (SAMP8) mouse model of aging, and in human
postmortem tissue from aged control patients (Smith et al.,
1991; Navarro and Boveris, 2004; Poon et al., 2004, 2006a,b;
Gokulrangan et al., 2007; Lam et al., 2009; Perluigi et al., 2010;
Perluigi et al., 2014; Pérez et al., 2010). Aberrant redox PTMs
of proteins may also contribute to the age-associated reduced
synaptic transmission and impaired induction of long-term
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FIGURE 2 | Redox PTMs of protein thiols are essential for normal cell physiology and contribute to aging and neurodegenerative diseases. (A) In young healthy
cells, redox PTMs are an integral part of the normal cell signaling: they can coordinately modulate the activity of multiple proteins depending on the local RONS
composition and levels. Redox PTMs regulate the function of proteins involved in essential pathways such as energy metabolism, protein folding and degradation,
and gene transcription. Redox PTMs are represented by a red dot on the target proteins. (B) During aging, imbalance between RONS production and the antioxidant
capacity of the cell leads to O/N stresses, and proteins may become differentially and/or aberrantly modified by redox PTMs, as represented by multiple red dots on
the target proteins. These redox PTMs can affect the function of target proteins, ultimately altering key pathways that contribute to the aging process.
(Continued)
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FIGURE 2 | Continued
(C) Drp1 is a GTPase protein involved in mitochondrial fission; when
activated, especially by S-nitrosation, Drp1 forms oligomers that wrap around
the mitochondrial outer membrane and scission it. Excessive levels of
S-nitrosated Drp1, as seen in AD, disrupt the physiological equilibrium
between mitochondrial fission and fusion, leading to increased mitochondrial
fission, and synaptic and neuronal damage. (D) PDI is an ER protein with a
dual isomerase and chaperone activity. S-nitrosation of PDI inhibits its
functions. Excessive S-nitrosation of PDI, as observed in AD, PD, and ALS,
leads to the accumulation of misfolded proteins in the ER and consequently,
to increase in ER stress and neuronal cell death. In ALS, PDI is recruited to
cytoplasmic inclusions containing ALS-associated proteins such as SOD1,
TDP-43, FUS, or VABP. S-nitrosation of PDI also increases insoluble
aggregates of ALS-associated mutant SOD1. (E) Parkin is an E3 ubiquitin
ligase that targets damaged proteins and mitochondria to the
ubiquitin-proteasome system and mitophagy. Loss-of-function mutations in
Parkin are associated with familial PD. Importantly, excessive and persistent
S-nitrosation of non-mutated Parkin, as detected in postmortem brains of
patients with sporadic PD, also inhibits Parkin activity, which impairs
ubiquitination of its substrate proteins and contributes to the accumulation of
damaged proteins and mitochondria and ultimately to neuronal cell injury and
death. (F) Hyperactivity of the extrasynaptic NMDAR leads to excessive
intracellular calcium, hypersynchrony and hyperexcitability of neurons, and
synaptic damage and excitotoxicity in AD. A new drug, NitroSynapsin, is
constituted of a memantine moiety and an added nitro group (NO2). It can
dampen the hyperactivity of NMDAR while preserving its physiological
function by binding inside the excessively opened channel and by acting as
an NO group donor, which triggers NMDAR inactivation through S-nitrosation
of its redox-sensitive Cys residues. NitroSynapsin treatment significatively
improves the pathological features associated with AD. TCA, tricarboxylic acid
cycle; OXPHOS, oxidative phosphorylation; RONS, reactive oxygen species
and reactive nitrogen species; Antiox, antioxidant capacity; Drp1, Dynamin
related protein 1; PDI, protein disulfide isomerase; ER, endoplasmic reticulum;
SOD1, superoxide dismutase 1; TDP-43, transactive response DNA binding
protein 43 kDa; FUS, Fused in sarcoma; VAPB, vesicle-associated membrane
protein; Ub, ubiquitin; NMDAR, N-methyl-D-aspartate receptor; AD,
Alzheimer’s disease; PD, Parkinson’s disease; ALS, amyotrophic lateral
sclerosis. All figures were created with BioRender.com.
potentiation (Foster and Norris, 1997; Foster and Kumar,
2002; Foster, 2006, 2007, 2012; Kumar et al., 2009, 2018;
Bodhinathan et al., 2010a,b; Oh et al., 2010; Bradley and
Steinert, 2016; Hidalgo and Arias-Cavieres, 2016; Muñoz et al.,
2020). For example, the redox-sensitive ryanodine receptor
3 (RyR3) essential for synaptic transmission and plasticity,
is nitrated in the cerebellum of aged rats (Gokulrangan
et al., 2007; Lanner et al., 2010; Abu-Omar et al., 2018;
Arias-Cavieres et al., 2018; Muñoz et al., 2020). Interestingly,
hyper-S-nitrosation of RyRs shifts these receptors from a
finely regulated state to unregulated Ca2+ leak channels (Bull
et al., 2008; Bellinger et al., 2009; Bodhinathan et al., 2010b;
Liu et al., 2012; Lacampagne et al., 2017; Muñoz et al.,
2020). S-glutathionylation of RyRs also compromises their
function (Bull et al., 2003; Hidalgo, 2005; Aracena-Parks et al.,
2006). Together, this suggests that redox PTMs of RyRs may
contribute to the progressive age-dependent dysregulation of
synaptic transmission.
There is a growing body of evidence however that conflicts
with the idea that RONS and associated redox PTMs of proteins
in aging are solely detrimental to cell function. The ‘‘redox
theory of aging’’ indeed presents the redox proteome as a
system that allows organisms to best adapt to a changing
environment and varied exposures (exposome) throughout their
lifespan, and which contributes to building progressive resilience
(Go and Jones, 2013; Jones, 2015; Jones and Sies, 2015).
It also states that the process of aging could be a gradual
breakdown of the redox proteome and redox metabolome, which
act together as adaptive interfaces supporting the interaction
between the genome and the exposome (Jones, 2015; Go
and Jones, 2017). Other studies have also demonstrated that
mitochondrial RONS can initiate a positive adaptive homeostasis
cascade following a non-linear response (termed mitohormesis);
both the dose and timing of RONS exposure determining
whether RONS have either a beneficial or detrimental effect
on cell function (Kawagishi and Finkel, 2014; Ristow, 2014;
Ristow and Schmeisser, 2014; Yun and Finkel, 2014). Mild O/N
stresses can indeed trigger a protective response that makes
organisms more resistant to future, greater, oxidative insults
and therefore increasing levels of RONS (and potentially of
redox PTMs of protein thiols) can be beneficial at the cellular
or organismal levels and can even promote healthspan and
lifespan (Kawagishi and Finkel, 2014; Ristow, 2014; Ristow
and Schmeisser, 2014; Yun and Finkel, 2014). It has been
hypothesized that aging results in a generalized decline in this
adaptive homeostasis, in particular through an age-dependent
attenuation of proteolytic activity and capacity (Pomatto and
Davies, 2018).
Besides, also contrary to the concept that RONS induce a bulk
accumulation of non-specific redox PTMs of protein thiols in
aging, a recent study that compared the redox Cys-proteome
in tissues of young (16-week-old) and old (80-week-old) mice
has shown that the overall levels of reversibly oxidized Cys
residues are very similar in young and aged tissues (Xiao
et al., 2020), which was consistent with previous observations
made in D. melanogaster (Menger et al., 2015). Interestingly,
it also found that young and aged tissues have largely distinct
redox proteomic signatures with different highly modified
Cys residues (Xiao et al., 2020). This demonstrates that a
profound and very specific remodeling of the redox signaling
landscape occurs during aging, which in turn induces tissue-
specific functional shifts. It remains to explore however whether
the redox PTMs that have been detected in aged tissue so
far contribute to either accelerating or slowing down the
the aging process. It is often difficult to ascertain whether
redox PTMs of protein thiols have beneficial or detrimental
effects on protein and cellular function, as exemplified by
Prdxs, which are ‘‘gerontogenes’’ that can prevent the age-
related decline in cognitive function and can increase healthspan
and lifespan (Neumann et al., 2003; Oláhová et al., 2008;
Timmermann et al., 2010; Kim et al., 2011; Nyström et al.,
2012). Indeed, because Prdxs are overoxidized with age (which
progressively inactivates their antioxidant activity), redox PTM
of Prdxs was initially considered as a detrimental factor
contributing to aging (Hall et al., 2009; Musicco et al.,
2009; Molin et al., 2011; Nyström et al., 2012). However,
because overoxidation of Prdxs also favors their chaperone
activity, it was later suggested that redox PTM of Prdxs
may constitute a positive adaption that helps counteract the
detrimental protein aggregation associated with aging (Nyström
et al., 2012). Somewhat related, redox-dependent dimerization
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of Prdx2 drives a Prdx2-dependent increase in overall life
expectancy in C. elegans (De Haes et al., 2014), suggesting
that redox PTM of Prdx2 plays a role in counteracting the
aging process. Therefore, further studies are required to fully
grasp the role played by redox PTMs of protein thiols in brain
aging and to explore whether redox PTMs may have different
effects (i.e., beneficial or detrimental) at different stages of the
aging process.
In the past few decades, additional factors have been
implicated in aging including low-grade chronic inflammation
(‘‘inflammaging’’; Franceschi et al., 2007; von Bernhardi et al.,
2015). Which one of the various factors contributing to the aging
process is the main initiator of brain aging remains unclear.
There are nevertheless many lines of evidence that suggest that
these various contributing factors exacerbate each other, and that
cellular redox dysregulation may be a common denominator (De
la Fuente and Miquel, 2009; Ortuño-Sahagún et al., 2014; Yin
et al., 2016). As a possible underlying molecular mechanism,
it has been suggested that redox PTM of NF-kB, a pivotal
transcription factor regulating inflammation, modulates NF-kB
activity and subsequently the inflammatory response during
aging (Ljubuncic et al., 2010; Zhang et al., 2013). Indeed, under
sustained O/N stresses (as seen in aging), tyrosine residues
of IκBα (one of NF-kB subunits) are nitrated, which leads
to a prolonged and excessive NF-kB activation and signaling
(Adler et al., 2007; Yakovlev et al., 2007). More integrated
studies of the complex process of aging would be required to
understand the interconnection and crosstalk between redox
PTMs of protein and the various factors contributing to
brain aging.
ROLE OF REDOX PTMs OF PROTEINS IN
NEURODEGENERATIVE CONDITIONS
In age-related neurodegenerative conditions such as AD, PD, and
ALS, an increase in O/N stresses and associated redox PTMs
has consistently been described; S-nitrosated, S-sulfonylated,
nitrated and carbonylated proteins are amongst the redox PTMs
detected in the cerebrospinal fluid, plasma and postmortem
brains and spinal cords of patients with AD, PD or ALS
(Markesbery, 1997; Jenner, 2003;Mitsumoto et al., 2008; Riederer
et al., 2009; Di Domenico et al., 2011; Sultana et al., 2011a,b;
Barone et al., 2012; Sultana and Butterfield, 2013; Zahid et al.,
2014). Crucially, these O/N stresses-induced PTMs are also
observed at the presymptomatic stages of neurodegenerative
diseases (Andrus et al., 1998; Aluise et al., 2010, 2011; Butterfield
et al., 2010, 2012; Hartl et al., 2012; Granold et al., 2015; Shen
et al., 2015). For example, redox proteomics on postmortem
brains from patients with preclinical AD (presymptomatic stage)
or with AD with mild cognitive impairment (symptomatic
stage) has shown that protein carbonylation increases at the
transition between the two clinical stages and correlates with
clinical features, pathology and biochemistry of AD (Butterfield
et al., 2010, 2012; Sultana et al., 2010; Aluise et al., 2011).
Together, this suggests that O/N stresses-induced PTMs are
not simply a late consequence of the disease progression
but that they play an active role in the pathophysiology of
neurodegenerative conditions.
Redox PTMs contribute to neurodegenerative conditions by
facilitating the aggregation of disease-associated proteins. For
instance, redox PTMs such as oxidation, sumoylation, and
nitration of amyloid β (Aβ) or α-synuclein (associated with
AD and PD, respectively) inhibit their degradation by the
ubiquitin/proteasome system and autophagy, which leads to
further accumulation and aggregation of their toxic products
(Kuo et al., 1998; Przedborski et al., 2001; Boutte et al., 2006;
Butterfield et al., 2010; Stefanis, 2012; Chavarría and Souza,
2013; Barrett and Timothy Greenamyre, 2015; Roher et al., 2017;
Savyon and Engelender, 2020).
Also, aberrant redox PTMs of proteins playing key roles in
cell physiology are consistently observed in neurodegenerative
conditions (Nakamura et al., 2013; Akhtar et al., 2016; Di
Domenico et al., 2017; Tramutola et al., 2017; Valle and Carrì,
2017; Dyer et al., 2019; Sbodio et al., 2019; Tegeder, 2019;
Nakamura and Lipton, 2020; Figures 2C–E). For example, the
redox-sensitive dynamin-related protein 1 (Drp1), a GTPase
involved in mitochondrial fission, is activated by S-nitrosation
(Drp1-SNO; Cho et al., 2009; Willems et al., 2015; Figure 2C).
Drp1 is aberrantly S-nitrosated in neurodegenerative disease as
high levels of Drp1-SNO and hyperactive Drp1 are detected
in postmortem brains and peripheral blood lymphocytes of
AD patients (Cho et al., 2009; Wang et al., 2009; Manczak
and Reddy, 2012; Wang S. et al., 2012). Crucially, exposure of
primary neuron cultures to Aβ leads to increase in Drp1-SNO,
excessive mitochondrial fission, impaired energy metabolism,
and neuronal cell loss, mimicking what is seen in AD, while
the use of a non-nitrosylable Drp1 mutant prevents these
detrimental effects (Cho et al., 2009; Wang et al., 2009;
Trushina et al., 2012; DuBoff et al., 2013; Joshi et al., 2017;
Pérez et al., 2017; Flannery and Trushina, 2019; Oliver and
Reddy, 2019). Therefore, S-nitrosation of Drp1 plays a key role
in the mitochondrial dynamic defects and neurodegeneration
observed in AD (Wang et al., 2009; Cho et al., 2010, 2013;
Nakamura and Lipton, 2020). The multifunctional protein PDI
is also aberrantly S-nitrosated in neurodegenerative conditions
as shown in postmortem spinal cords of ALS patients and
transgenic SOD1G93A mouse model of ALS as well as in
postmortem brains of AD and PD patients (Uehara et al.,
2006; Walker et al., 2009; Chen et al., 2013; Jeon et al.,
2014; Conway and Harris, 2015; Figure 2D). PDI is an
ER protein, but in disease conditions, triggered by redox
PTMs in particular, it can translocate to the cytoplasm where
it localizes to inclusions containing ALS-associated proteins
(Turano et al., 2002; Honjo et al., 2011; Walker and Atkin,
2011; Farg et al., 2012; Jeon et al., 2014; Valle and Carrì,
2017; Matsusaki et al., 2020; Parakh et al., 2020). PDI, as an
oxidoreductase chaperone, catalyzes the maturation of disulfide
bond-containing proteins through oxidation and isomerization
functions (Gonzalez et al., 2010). However, S-nitrosation
of PDI Cys residues in its two thioredoxin-like domains
inactivates both its chaperone and isomerase activities, which
leads to the accumulation of misfolded proteins, in particular
ALS-associated proteins like SOD1, and to a persistent ER
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stress that ultimately triggers neuronal injury and death (Uehara
et al., 2006; Walker et al., 2009; Chen et al., 2012, 2013;
Jeon et al., 2014; Medinas et al., 2018; Matsusaki et al.,
2020). Similarly, excessive levels of S-nitrosation of another
multifunctional protein, Prdx2, are observed in dopaminergic
neurons differentiated from induced pluripotent stem cells from
PD patients as well as in PQ/MB-exposed PD mouse model
and postmortem brains of patients with PD (Fang et al., 2007;
Sunico et al., 2016). Importantly, S-nitrosation of Prdx2 breaks
the normal redox cycle that regenerates Prdx2, inhibits its
peroxidase activity, and reduces its overoxidation (which is
essential for stabilization of Prdx2 chaperone complexes; Jang
et al., 2004; Fang et al., 2007; Engelman et al., 2013; Zhang
et al., 2019). Together, this suggests that aberrant redox
PTM of Prdx2 Cys residues impairs its antioxidant and
chaperone functions, leading to accumulation of misfolded
proteins and O/N stresses in neurodegenerative conditions.
Neuroinflammation is another essential contributing factor to
neurodegeneration (Hsieh and Yang, 2013; Guzman-Martinez
et al., 2019). Crucially, redox PTMs of protein thiols have been
implicated in inflammation regulation (Gloire and Piette, 2009;
Nakamura et al., 2013; Ryan et al., 2014; Gorelenkova Miller
and Mieyal, 2015). For instance, S-glutathionylation of various
proteins of the NF-kB pathway can modulate the inflammatory
response in different cell types, and it has been suggested
that S-glutathionylation of protein thiols plays a key role in
neuroinflammation in neurodegenerative conditions (Reynaert
et al., 2006; Sabens Liedhegner et al., 2012; Gorelenkova
Miller and Mieyal, 2015; Cha et al., 2017). Thus, redox PTMs
of protein thiols can detrimentally impair the function of
target proteins, which in turn can dysregulate many important
pathways such as mitochondrial function, proteostasis, ER stress,
neuroinflammation, and contribute to the neurodegenerative
process (Sabens Liedhegner et al., 2012; Nakamura et al., 2013;
Gorelenkova Miller and Mieyal, 2015; Nakato et al., 2015; Valle
and Carrì, 2017; Nakamura and Lipton, 2020).
Aberrant redox PTMs have been described in several proteins
that can be mutated in the familial forms of neurodegenerative
conditions. Importantly, redox PTMs of non-mutated disease-
associated proteins can phenocopy the effect of rare genetic
mutations (Nakamura et al., 2013). For example, mutations
in Parkin in patients with early-onset autosomal recessive
juvenile PD impairs its E3 ubiquitin ligase activity, which leads
to an abnormal accumulation of protein aggregates and cell
death (Pankratz and Foroud, 2007; Nakamura et al., 2013;
Arkinson and Walden, 2018; Figure 2E). Similar detrimental
effects on Parkin function are observed in non-mutated Parkin
modified by S-nitrosation (Chung et al., 2004; Yao et al., 2004;
Sunico et al., 2013). Levels of S-nitrosated Parkin are increased
in postmortem tissues of patients with sporadic PD, which
implicates S-nitrosation of Parkin in the pathophysiology of
these forms of PD (Chung et al., 2004; Meng et al., 2011;
Sunico et al., 2013). Therefore, O/N stresses-induced PTM
of protein thiols has been proposed to play an important
role in the pathophysiology of the most common forms of
neurodegenerative conditions (Sabens Liedhegner et al., 2012;
Nakamura et al., 2013; Valle and Carrì, 2017; Dyer et al., 2019).
THE THERAPEUTIC POTENTIAL OF
REDOX PTMs OF PROTEINS
Given the contribution of O/N stresses in neurodegenerative
conditions, therapeutic strategies aiming at reducing O/N
stresses using common free radical scavengers such as coenzyme
Q10 or Vitamin E have been tested in clinical trials for these
conditions, but without much success (Feng and Wang, 2012;
Filograna et al., 2016). Mainly due to a lack of appropriate
biomarkers, there is still little evidence however that these
interventions effectively reduce O/N stresses levels in the
patients’ central nervous system. Also, the antioxidants tested
target specific RONS but it is not known whether the targeted
RONS are implicated in neurodegenerative disease. Indeed, not
all RONS are equivalent (Murphy et al., 2011) and only a
subset of specific RONS is likely implicated in a given disease
state. Physiological levels of RONS are essential for normal
cell function and RONS can be beneficial for healthspan and
lifespan (Kawagishi and Finkel, 2014; Ristow and Schmeisser,
2014; Ristow, 2014; Yun and Finkel, 2014), therefore globally
reducing RONS levels may not only fail to provide therapeutic
benefits but may also trigger detrimental side-effects (Kawagishi
and Finkel, 2014; Nakamura and Lipton, 2016). These represent
few of the factors thatmay have contributed to the limited success
of antioxidant-based therapeutic approaches for the treatment of
neurodegenerative conditions.
As an alternative redox-based therapeutic approach, it has
been proposed that modulation of redox PTMs of proteins
playing part in the neurodegenerative process using small
molecules could help prevent disease-associated dysfunction of
these proteins and restore their normal activity (Lipton et al.,
2002; Wani et al., 2014; Nakamura and Lipton, 2016). This
approach has been shown to provide significant therapeutic
benefits in several rodent models of neurological conditions.
For example, deprenyl/selegiline and its derivatives (CGP3466B,
TCH346), used in early PD (Moore and Saadabadi, 2020), has
been shown to bind GAPDH (Kragten et al., 1998) and prevent
S-nitrosation of its catalytic site (Hara et al., 2006b). S-nitrosation
is essential for GAPDH function as it increases its binding
to E3 ubiquitin-protein ligase Siah1, which leads to GAPDH
translocation to the nucleus and its activity as a transcriptional
activator of the apoptotic cascade (Sawa et al., 1997; Kragten et al.,
1998; Hara et al., 2005, 2006a,b; Sen et al., 2008). CGP3466B, by
preventing GAPDH S-nitrosation, blocks the apoptotic cascade
induced by S-nitrosated GAPDH. Accordingly, CGP3466B has
been shown to reduce neuronal cell death in animal models of
PD (Andringa and Cools, 2000; Andringa et al., 2000; Waldmeier
et al., 2000; Hara et al., 2006b; Naoi et al., 2020), ALS (Sagot et al.,
2000; Waldmeier et al., 2000), AD (Sen et al., 2018), muscular
dystrophy (Erb et al., 2009; Yu et al., 2013), cocaine addiction
(Xu et al., 2013; Harraz and Snyder, 2015), traumatic brain
injury (Liang et al., 2017), and ischemia (Simon et al., 2001;
Ahmari et al., 2020). Together, these studies highlight the
therapeutic potential of targeting redox PTMs of specific
proteins to modulate protein function and to counteract the
neurodegenerative process.
Frontiers in Aging Neuroscience | www.frontiersin.org 9 September 2020 | Volume 12 | Article 254
Finelli Redox PTMs in the Brain
Based on the fact that O/N stresses-induced PTM of
proteins can affect the conformation of target proteins and
their binding affinity to other proteins and potential drugs,
pathologically-activated therapeutics have been developed to
interact with ‘‘cryptic’’ sites of the target proteins that are
exposed only under pathological conditions (Lipton, 2007).
This approach aims to reduce the pathological activity of
the target protein and to spare its normal activity in order
to prevent any side-effects associated with drug treatment
(Lipton, 2007). Such approach has been used to dampen the
pathological hyperactivity of the N-methyl-D-aspartate receptor
(NMDAR; Figure 2F). NMDAR is a glutamate-gated ion channel
permeable to Ca2+ and is essential for neurotransmission,
learning, and memory formation (Lipton, 2006). Hyperactivity
of NMDAR is a common disease mechanism for many
neurodegenerative conditions (Lipton and Rosenberg, 1994), and
plays a critical role in excitotoxicity and synaptic damage in
AD (Li et al., 2011; Talantova et al., 2013; Molokanova et al.,
2014). To reduce NMDAR hyperactivity, the FDA-approved
aminoadamantane compound, Memantine, an uncompetitive
fast-off rate NMDAR antagonist that acts as an open-channel
blocker was used initially (Chen et al., 1992; Chen and
Lipton, 1997; Lipton, 2006). To improve the limited effect of
Memantine on disease symptoms, and based on the observation
that S-nitrosation of NMDAR reduces its activity (Lipton and
Rosenberg, 1994; Choi et al., 2000; Lipton, 2006; Takahashi
et al., 2007; Molokanova et al., 2014), NitroSynapsin (YQW-
036, NitroMemantine), a derivative of Memantine that combines
the aminoadamantane moiety and a nitro group was later
synthesized and tested (Lipton, 2006, 2007; Wang et al., 2006;
Talantova et al., 2013). NitroSynapsin utilizes the high-affinity
Memantine binding site on NMDARs to target the nitro
group for interaction with the S-nitrosation/inhibitory site
of NMDAR (which is external to the Memantine-binding
site); this increases NMDAR S-nitrosation and further reduces
its excessive activity (Takahashi et al., 2015; Ghatak et al.,
2020). Importantly, this new drug has been shown to reduce
synaptic degeneration and improve the disease phenotype of
a 3xTg AD mouse model (Talantova et al., 2013), a rat
model of vascular dementia (Takahashi et al., 2015), a MEF2C
haploinsufficiency mouse model of autism (Tu et al., 2017),
a tuberous sclerosis mouse model (Okamoto et al., 2019)
and an hAPP-J20 AD mouse model (Ghatak et al., 2020).
Very recently, the effect of NitroSynapsin on neuronal activity
has also been explored in neurons and cerebral organoids
derived from human induced pluripotent stem cells (Ghatak
et al., 2020). Interestingly, NitroSynapsin (but not Memantine)
dampens the AD-associated increase in spontaneous action
potentials and hypersynchronous network activity, suggesting
that NitroSynapsin is more effective thanMemantine as a human
AD drug (Ghatak et al., 2020), which will be tested in future
clinical trials.
The potential synergistic effect on drug efficacy of the
combination of an existing drug and a nitro group has also
been tested with the FDA-approved compound Clomethiazole
(CMZ). CMZ is a well-established neuroprotective potentiator
of the redox-sensitive gamma-aminobutyric acid receptor
(GABAR; Castel and Vaudry, 2001; Wilby and Hutchinson,
2004; Gasulla et al., 2012; Dejanovic and Schwarz, 2014;
Vandevrede et al., 2014; Calvo and Beltrán González, 2016).
Crucially, NMZ/GT-1061, a CMZ compound analog possessing
a nitro group, was shown in AD mouse models to significantly
reduce Aβ deposition and cognitive decline, and to restore
neuronal plasticity (Qin et al., 2012; Luo et al., 2015,
2016; Hollas et al., 2019); however, it remains unknown
whether NO-mediated redox PTMs on GABAR play a part
in the improved beneficial therapeutic effects provided by
NMZ treatment.
Given the importance of O/N stresses and associated
modifications in the onset and progression of many diseases,
redox PTMs, especially irreversible redox PTMs, have been
proposed as potential circulating biomarkers for a range of
conditions including cardiovascular and pulmonary diseases
(Di Domenico et al., 2011; Butterfield et al., 2014; Frijhoff
et al., 2015; Mnatsakanyan et al., 2018; Tomin et al.,
2019). Several studies have explored the proteins modified by
irreversible redox PTMs (e.g., carbonylation) in cerebrospinal
fluid and blood of AD and control patients and have detected
differences in oxidation levels of a small number of proteins
(Choi et al., 2002; Korolainen et al., 2007; Korolainen and
Pirttilä, 2009; Cocciolo et al., 2012) suggesting that specific
redox-modified proteins could be used as biomarkers for
neurodegenerative conditions. Major technical challenges have
however hindered so far the discovery of the full spectrum
of proteins modified by redox PTMs in clinical samples
(Delobel et al., 2016; Mnatsakanyan et al., 2018). Another
major hurdle in the use of redox-modified proteins as
biomarkers for neurodegenerative conditions is the limited
passage of proteins or protein fragments through the blood-
brain barrier (Di Domenico et al., 2011; Wang et al., 2012a;
Hampel et al., 2018). So far, a handful of proteins present
in biofluids of patients has been identified as potential
biomarkers for neurodegenerative conditions, including Tau,
Aβ, and neurofilament light (Hampel et al., 2018; Lewczuk
et al., 2018; Robey and Panegyres, 2019; Ashton et al., 2020).
Given that redox PTMs of these proteins contribute to the
pathophysiology of neurodegenerative diseases (Horiguchi et al.,
2003; Reynolds et al., 2006; Alkam et al., 2008; Kummer et al.,
2011; Reyes et al., 2011), assessing the redox status of these
proteins could provide crucial information, for example on
the disease stage, which could potentially help follow disease
progression or assess the efficacy of new drugs. It is therefore
essential to further improve the sensitivity and robustness of
current methodologies used to detect redox PTMs in clinical
samples in order to discover redox-modified proteins that
could discriminate pathological vs. healthy states and that
could potentially be used as diagnostic or prognostic tools for
neurodegenerative conditions.
CONCLUSION
Redox PTMs of protein thiols play an important role in normal
cell physiology, brain aging, and in the pathophysiology of
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several neurodegenerative conditions, including AD, PD, and
ALS. Aberrant redox PTMs can occur in response to O/N stresses
and contribute to neurodegeneration by disrupting numerous
pathways, from proteostasis to mitochondrial dynamics and
function. Further developments in mass spectrometry-based
redox proteomics will allow to explore the full redox proteome
and to identify proteins and pathways modulated by specific
redox PTMs in physiology and disease. A better understanding
of drug targets’ redox regulations in disease conditions would
also be required to design more effective and selective redox-
based therapeutic approaches for neurodegenerative conditions.
Approaches that would modulate redox PTMs on specific target
proteins to elicit a selective cellular response could also be
tested as an alternative redox-based therapeutic strategy for
neurodegenerative disease.
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